Breaking News Instant updates and real-time market news.

AKRX

Akorn

$7.49

0.11 (1.49%)

, FSNUY

Fresenius SE

$0.00

(0.00%)

17:27
11/06/18
11/06
17:27
11/06/18
17:27

Akorn says can't predict timing of Fresenius appeal decision

The company said in tonight's earnings release, "What are Akorn's expectations for the appeal of the Delaware Court of Chancery ruling? We believe in the merit of our appeal, but the ultimate decision is up to the Supreme Court of the State of Delaware, which will hear oral arguments on December 5, 2018. We cannot predict the timing of the decision, however, we were pleased that the Court granted our Motion to Expedite. What happens if Akorn loses the appeal? When will you give guidance? It is premature to communicate any forward-looking guidance; we appreciate your patience as we work through the appeal process. If we do not prevail, we will continue our focus on creating long-term shareholder value and advancing our mission to improve patients' lives through the quality, availability and affordability of our products. What's the value proposition for shareholders now? Akorn has a long history of creating shareholder value through the manufacture and marketing of generic and branded prescription pharmaceuticals, as well as animal and consumer health products. We specialize in difficult-to-manufacture sterile and non-sterile dosage forms including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. While the ongoing litigation has created distractions and included many misleading and false allegations about Akorn, our commitment to running the business, complying with regulatory requirements and pursuing avenues for growth has not changed."

AKRX

Akorn

$7.49

0.11 (1.49%)

FSNUY

Fresenius SE

$0.00

(0.00%)

AKRX Akorn
$7.49

0.11 (1.49%)

10/04/18
CHLM
10/04/18
UPGRADE
Target $11
CHLM
Buy
Akorn upgraded to Buy from Hold at Craig-Hallum
10/04/18
10/04/18
UPGRADE
Target $11

Buy
Akorn upgraded to Buy after 'overreaction' to court rule at Craig-Hallum
As previously reported, Craig-Hallum analyst Matt Hewitt upgraded Akorn (AKRX) to Buy from Hold saying that while the ruling in favor of Fresenius (FMS) by the Deleware Court of Chancery was a major disappointment for investors, the 50%-plus drop in Akorn's stock price these past few days is unwarranted and values the company well below what it is worth on a standalone basis. The analyst also lowered his price target for Akorn's shares to $11 from $14.
10/17/18
PIPR
10/17/18
UPGRADE
Target $9
PIPR
Overweight
Akorn upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem upgraded Akorn (AKRX) to Overweight and raised his price target for the shares to $9 from $5. After taking a closer look at the company's base generics business in the wake of the lower court decision that sided with Fresenius (FSNUY) in its efforts to terminate its merger with Akorn, Amsellem believes annual EBITDA of no worse than $125M-$135M starting in 2019 is realistic. The analyst says that based on trends associated with a number of its notable products, as well as his recent conversation with management, he believes a picture of sustainable EBITDA is emerging at Akorn that is better than what he had previously envisioned. Assuming Akorn loses its appeal, management "strongly suggested" that it address its cost structure, Amsellem tells investors in a research note.
10/17/18
10/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Infosys (INFY) upgraded to Market Perform from Underperform at William Blair WITH analyst Maggie Nolan citing Q2 results. 2. American Airlines (AAL), Delta Air Lines (DAL), and United Continental (UAL) upgraded to Buy from Hold at Deutsche Bank. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying based on trends associated with a number of its notable products, as well as his recent conversation with management, he believes a picture of sustainable EBITDA is emerging at Akorn that is better than what he had previously envisioned. 4. Workday (WDAY) upgraded to Outperform from Market Perform at Bernstein with analyst Mark Moerdler saying he determined that even if the ERP market moves reasonably slowly to the Cloud, it is large enough and the fact there are only a few vendors with a competitive SaaS solution should allow Workday to continue to gain share. 5. Domino's Pizza (DPZ) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying the pullback in the stock price is overdone and expects accelerated cost savings and solid comps to yield higher earnings, raising his FY20 EPS view to $12.01 from $11.72. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FSNUY Fresenius SE
$0.00

(0.00%)

09/12/18
DBAB
09/12/18
NO CHANGE
Target $34
DBAB
Hold
Judge ruling in Akorn case unlikely in coming days, says Deutsche Bank
After dialing into yesterday's teleconference scheduled by Judge Laster to discuss the roadmap ahead for Fresenius SE's (FSNUY) attempt to terminate its acquisition of Akorn (AKRX), Deutsche Bank analyst Gregg Gilbert says he did not hear anything to suggest that the judge is leaning one way or the other. It feels like a ruling is not likely to happen in the coming days, Gilbert tells investors in a research note. The analyst continues to assume a ruling will come by sometime in November. He also believes the judge continues to suggest that he knows he will not have the final say, suggesting that an appeal is inevitable. Gilbert keeps a Hold rating on Akorn with a price target of $34.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $5
PIPR
Neutral
Akorn price target lowered to $5 from $34 at Piper Jaffray
Piper Jaffray analyst David Amsellem lowered his price target for Akorn (AKRX) to $5 from $34 after a Delaware court ruled in favor of Fresenius (FSNUY) in its efforts to terminate its merger agreement with Akorn. While Akorn shares are essentially reflecting the reality that the company will be a stand-alone entity, the current state of the business suggests that there is still potential for further downside, Amsellem tells investors in a research note titled "Apres Fresenius, Le Deluge; Staying Far Away From AKRX Shares." The analyst reiterates a Neutral rating on the shares.
10/02/18
RBCM
10/02/18
NO CHANGE
Target $10
RBCM
Sector Perform
Akorn price target lowered to $10 from $27 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Akorn (AKRX) to $10 and kept his Sector Perform rating, saying his bearish case outcome materialized from the Delaware court ruling in favor of Fresenius (FSNUY) in its efforts to terminate its merger agreement with Akorn. The analyst notes that the subsequent price decline reflects the "standalone FDA regulatory concerns and only limited optionality for success on appeal".
10/03/18
JEFF
10/03/18
NO CHANGE
Target $6
JEFF
Hold
Jefferies expects Akorn to remain independent, cuts price target to $6 from $34
Jefferies analyst David Steinberg lowered his price target for Akorn (AKRX) to $6 from $34 after Judge Laster ruled in favor of Fresenius (FSNUY), allowing the company to withdraw from its agreement to acquire Akorn. The generic drugmaker closed yesterday up 29c to $5.65. While Akorn will appeal, Steinberg assumes the company will remain independent. The analyst forecasts a quarterly revenue run rate of $175M with annual earnings power in the 35c-40c per share range. In the long-term, if the 64 abbreviated new drug application pipeline remains intact, the business "should grow nicely," Steinberg tells investors in a research note. However, the analyst has near-term concerns about Akorn's "over-reliance on one large product," a lack of drug application filings this year, and its ongoing manufacturing deficiencies. He keeps a Hold rating on the shares.

TODAY'S FREE FLY STORIES

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/18/18
11/18
04:55
11/18/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

PDVW

pdvWireless

$39.84

0.06 (0.15%)

16:30
11/17/18
11/17
16:30
11/17/18
16:30
Conference/Events
pdvWireless management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.49

0.23 (0.40%)

16:28
11/17/18
11/17
16:28
11/17/18
16:28
Conference/Events
CBS management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

THS

TreeHouse

$51.92

0.72 (1.41%)

, CAG

Conagra Brands

$33.09

0.66 (2.04%)

12:54
11/17/18
11/17
12:54
11/17/18
12:54
Periodicals
Treehouse Foods stock may have room to gain, Barron's says »

Treehouse Foods (THS)…

THS

TreeHouse

$51.92

0.72 (1.41%)

CAG

Conagra Brands

$33.09

0.66 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$194.23

1.83 (0.95%)

12:51
11/17/18
11/17
12:51
11/17/18
12:51
Periodicals
Amgen may be 'a remedy' for tougher times, Barron's says »

Amgen may be a stock that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AAPL

Apple

$193.42

2 (1.04%)

, LITE

Lumentum

$41.50

0.46 (1.12%)

12:47
11/17/18
11/17
12:47
11/17/18
12:47
Periodicals
Apple stock could continue to slide, Barron's says »

Apple's (AAPL) stock…

AAPL

Apple

$193.42

2 (1.04%)

LITE

Lumentum

$41.50

0.46 (1.12%)

QRVO

Qorvo

$66.32

1.18 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$56.39

0.9 (1.62%)

, RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

12:41
11/17/18
11/17
12:41
11/17/18
12:41
Periodicals
Investors may find bargains among oil, natural gas stocks, Barron's says »

Investors have been…

APC

Anadarko

$56.39

0.9 (1.62%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

CVX

Chevron

$119.14

2.18 (1.86%)

BP

BP

$40.85

-0.3 (-0.73%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Jan

  • 22

    Jan

LB

L Brands

$35.28

-0.41 (-1.15%)

, JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

12:34
11/17/18
11/17
12:34
11/17/18
12:34
Periodicals
Kohl's, Target set to thrive this holiday season, Barron's says »

Store chains have been…

LB

L Brands

$35.28

-0.41 (-1.15%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

TJX

TJX

$51.47

-0.98 (-1.87%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TIF

Tiffany

$106.48

0.52 (0.49%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TGT

Target

$79.67

-1.09 (-1.35%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

09:18
11/17/18
11/17
09:18
11/17/18
09:18
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.46

-0.12 (-0.72%)

F

Ford

$9.05

-0.26 (-2.79%)

GM

General Motors

$35.76

0.21 (0.59%)

HMC

Honda

$28.21

0.01 (0.04%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$116.87

-0.02 (-0.02%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$26.30

-0.2 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.